Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –
— 美國東部時間下午 5:00 /太平洋時間下午 2:00 將進行電話會議和網絡直播 —
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 16, 2024-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.
加利福尼亞州阿拉米達--(美國商業資訊)--2024年4月16日-- Exelixis, Inc. 納斯達克股票代碼：EXEL）今天宣佈，其2024年第一季度財務業績將在市場收盤後於2024年4月30日星期二公佈。美國東部時間下午 5:00 /太平洋時間下午 2:00，Exelixis管理層將主持電話會議和網絡直播，討論結果並提供一般業務最新情況。該公司的網站可通過互聯網訪問該活動。
To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on www.exelixis.com for one year.
要參加電話會議，請使用此處進行註冊 鏈接。註冊後，將提供撥入號碼和唯一的 PIN 碼以加入通話。要訪問網絡直播鏈接，請登錄 www.exelixis.com 然後前往 “投資者與新聞” 標題下的 “活動日曆” 頁面。電話會議的網絡直播重播也將存檔於 www.exelixis.com 爲期一年。
About Exelixis
關於 Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
Exelixis是一家雄心勃勃的全球腫瘤公司，致力於在癌症治療的最前沿創新下一代藥物和方案。在卓越的藥物發現和開發能力的推動下，我們正在迅速發展我們的產品組合，通過我們具有臨床差異化的小分子、抗體藥物偶聯物和其他生物療法產品線，靶向越來越多的腫瘤類型和適應症。這種全面的方法利用數十年來對我們的科學和合作夥伴關係的強大投資來推進我們的研究計劃，擴大我們的旗艦商業產品CABOMETYX的影響力 （卡博贊替尼）。Exelixis的驅動力是大膽的科學追求，即創造變革性的治療方法，讓更多的患者對未來充滿希望。有關該公司及其幫助癌症患者恢復健康、延長壽命的使命的信息，請訪問 www.exelixis.com，關注 @ExelixisInc 在 X（Twitter）上，比如 Exelixis, Inc. 在 Facebook 上關注吧 Exelixis 在領英上。
Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.
Exelixis、Exelixis 徽標和 CABOMETYX 是美國的註冊商標。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416694147/en/
Investors Contact:
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com
投資者聯繫方式：
Varant Shirvanian
投資者關係董事
Exelixis, Inc.
650-837-7917
vshirvanian@exelixis.com
Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
媒體聯繫人：
哈爾·麥金斯
適用於 Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
Source: Exelixis, Inc.
來源：Exelixis, Inc.
譯文內容由第三人軟體翻譯。